Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

We came across a bullish thesis on Bristol-Myers Squibb Company (BMY) on Disruptive analytics’ Substack by Magnus Ofstad. In ...

Analyst Terence Flynn of Morgan Stanley maintained a Sell rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target of ...

Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the latter part of the year.

We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...

Bristol-Myers Squibb Company (BMY)’s share was trading ... A standout in BMY’s pipeline is Cobenfy, a drug for schizophrenia that has already outperformed other branded schizophrenia treatments.

The new drug Cobenfy, formerly known as KarXT, is manufactured by Bristol Myers Squibb, a global biopharmaceutical company. The drug became available by prescription in retail pharmacies across ...

Many stocks don't offer particularly high yields. The stocks in the S&P 500, for instance, average a yield of just 1.3%. That's not a terribly exciting rate of return on dividends for income investors ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar ...